Sort by
Keyphrases
Allergen
10%
Change from Baseline
10%
Dupilumab
100%
Dysphagia
50%
Endoscopic Features
10%
Eosinophil Count
20%
Eosinophil Infiltration
10%
Eosinophilic Esophagitis
100%
Eosinophils
30%
Erythema
10%
Esophageal Distensibility
30%
Field Reduction
10%
High-power Field
20%
Histologic
10%
Histological Score
10%
Histopathological Features
20%
Inflammatory Diseases
10%
Injection Site
10%
Interleukin-13 (IL-13)
10%
Interleukin-4 Receptor
10%
Mean Reduction
10%
Monoclonal Antibody
10%
Nasopharyngitis
10%
Patient-Reported Outcomes Measurement Information System (PROMIS)
30%
Phase II Study
10%
Phase II Trial
10%
Placebo
60%
Placebo Groups
30%
Randomized Trial
100%
Reference Measure
20%
Scoring System
10%
Severity Score
10%
Straumann
30%
Subcutaneous Injection
10%
Type 2 Inflammation
10%
United States
10%
Medicine and Dentistry
Allergen
10%
Diseases
20%
Dupilumab
100%
Eosinophil
50%
Eosinophilic
10%
Eosinophilic Esophagitis
100%
Human Monoclonal Antibody
10%
Inflammatory Disorder
10%
Injection Site Erythema
10%
Interleukin 4 Receptor
10%
Patient-Reported Outcome
30%
Placebo
90%
Plummer-Vinson Syndrome
50%
Rhinopharyngitis
10%
Scoring System
10%
Subcutaneous Injection
10%
Pharmacology, Toxicology and Pharmaceutical Science
Allergen
10%
Diseases
20%
Dupilumab
100%
Dysphagia
50%
Eosinophilic Esophagitis
100%
Human Monoclonal Antibody
10%
Inflammation
10%
Inflammatory Disease
10%
Injection Site Erythema
10%
Interleukin 4 Receptor
10%
Placebo
90%
Rhinopharyngitis
10%
Subcutaneous Injection
10%